CL2015002412A1 - Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012) - Google Patents

Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)

Info

Publication number
CL2015002412A1
CL2015002412A1 CL2015002412A CL2015002412A CL2015002412A1 CL 2015002412 A1 CL2015002412 A1 CL 2015002412A1 CL 2015002412 A CL2015002412 A CL 2015002412A CL 2015002412 A CL2015002412 A CL 2015002412A CL 2015002412 A1 CL2015002412 A1 CL 2015002412A1
Authority
CL
Chile
Prior art keywords
daptomycin
pharmaceutical composition
solid pharmaceutical
composition
solid
Prior art date
Application number
CL2015002412A
Other languages
English (en)
Inventor
Sandra O'connor
Sophie Sun
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002412(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of CL2015002412A1 publication Critical patent/CL2015002412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICIÓN SOLIDA DE DAPTOMICINA DONDE UNA CANTIDAD DE IA COMPOSICION FARMACÉUTICA SÓLIDA DE DAPTOMICINA QUE CONTIENE 500 MG DE DAPTOMICINA SE DISUELVE EN 10 ML DE CLORURO DE SODIO ACUOSO AL 0.9% EN MENOS DE 5 MINUTOS A ALREDEDOR DE 25°C DONDE LA COMPOSICION FARMACÉUTICA SOLIDA DE DAPTOMICINA SE OBTIENE POR: A. FORMACION DE UNA SOLUCION ACUOSA DE DAPTOMICINA QUE COMPRENDE DAPTOMICINA A UN PH DE ALREDEDOR DE 4,5-8,0, Y B. CONVE RSION DE IA SOLUCION ACUOSA DE DAPTOMICINA EN IA COMPOSICION FARMACÉUTICA SÓLIDA DE DAPTOMICINA. TAMBIÉN SE RELACIONA CON UN PRODUCTO FARMACÉUTICO QUE COMPRENDE LA COMPOSICION SOLIDA DE DAPTOMICINA; EL MÉTODO DE FABRICACIÓN DE LA COMPOSICION FARMACÉUTICA SOLIDA, Y EL USO PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS.
CL2015002412A 2009-11-23 2015-08-27 Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012) CL2015002412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
CL2015002412A1 true CL2015002412A1 (es) 2016-02-05

Family

ID=44060422

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001336A CL2012001336A1 (es) 2009-11-23 2012-05-23 Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
CL2015002412A CL2015002412A1 (es) 2009-11-23 2015-08-27 Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2012001336A CL2012001336A1 (es) 2009-11-23 2012-05-23 Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.

Country Status (33)

Country Link
US (3) US8835382B2 (es)
EP (2) EP2504353B2 (es)
JP (3) JP6041673B2 (es)
CN (3) CN102712677B (es)
AR (2) AR079127A1 (es)
AU (1) AU2010321531C1 (es)
BR (1) BR112012012406B1 (es)
CA (1) CA2781666C (es)
CL (2) CL2012001336A1 (es)
CO (1) CO6541585A2 (es)
CR (1) CR20120271A (es)
CY (1) CY1120854T1 (es)
DK (1) DK2504353T4 (es)
DO (1) DOP2012000140A (es)
EC (1) ECSP12011939A (es)
ES (1) ES2686331T5 (es)
FI (1) FI2504353T4 (es)
HR (1) HRP20181380T4 (es)
HU (1) HUE039967T2 (es)
IL (1) IL219891B (es)
LT (1) LT2504353T (es)
MX (1) MX2012005993A (es)
NZ (1) NZ600118A (es)
PE (2) PE20121517A1 (es)
PL (1) PL2504353T5 (es)
PT (1) PT2504353T (es)
RS (1) RS57566B2 (es)
RU (1) RU2607526C2 (es)
SG (1) SG10201407724YA (es)
SI (1) SI2504353T2 (es)
TR (1) TR201812823T4 (es)
TW (2) TWI606838B (es)
WO (1) WO2011063419A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
TR201812823T4 (tr) 2009-11-23 2019-02-21 Cubist Pharmaceuticals Llc Lipopeptit bileşimleri ve ilgili yöntemler.
CN103429228B (zh) 2011-01-05 2016-10-26 赫士睿股份有限公司 万古霉素的喷雾干燥
KR20140037877A (ko) * 2011-05-26 2014-03-27 큐비스트 파마슈티컬즈 인코포레이티드 Cb-183,315 조성물 및 관련 방법
CN104168908A (zh) * 2012-01-12 2014-11-26 细胞基因公司 罗米地新制剂及其用途
EP3287138A1 (en) * 2012-08-23 2018-02-28 Agila Specialties Private Limited Improved daptomycin injectable formulation
ES2552754T1 (es) 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN111093625A (zh) * 2017-08-31 2020-05-01 埃克斯利亚制药有限公司 达托霉素制剂
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
CN114828873A (zh) * 2019-12-26 2022-07-29 尼普洛株式会社 含有达托霉素的稳定的冷冻干燥制剂
WO2021170807A1 (en) 2020-02-28 2021-09-02 Xellia Pharmaceuticals Aps Daptomycin formulation
BR112022015170A2 (pt) * 2020-03-12 2022-10-11 Baxter Int Formulações de daptomicina contendo uma combinação de sorbitol e manitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
KR102218688B1 (ko) * 2020-06-25 2021-02-22 주식회사 클린텍 무선제어기능을 구비한 고압세척기
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
NZ213731A (en) 1984-10-09 1988-04-29 Lilly Co Eli A-21978c derivatives
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
EP0386951A3 (en) * 1989-03-06 1992-05-20 Eli Lilly And Company An improved diluent formulation for daptomycin
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (es) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
ES2119898T3 (es) 1992-04-20 1998-10-16 Abbott Lab Procedimiento de produccion de vancomicina.
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
ES2259845T3 (es) 1998-09-25 2006-10-16 Cubist Pharmaceuticals, Inc. Uso de la daptomicina.
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
IL150225A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
KR20080056308A (ko) * 2000-06-21 2008-06-20 큐비스트 파마슈티컬즈 인코포레이티드 항미생물제의 경구 흡수를 개선하기 위한 조성물 및 방법
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
KR20030081353A (ko) 2000-12-18 2003-10-17 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US20050027113A1 (en) 2001-08-06 2005-02-03 Miao Vivian Pak Woon Compositions and methods relating to the daptomycin biosynthetic gene cluster
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
CA2491466A1 (en) 2002-07-09 2004-01-15 Sharlene Adams Methods and compositions relating to isoleucine boroproline compounds
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
BRPI0607168A2 (pt) * 2005-02-14 2009-08-11 Venus Remedies Ltd terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2049142B2 (en) 2006-07-26 2016-01-20 Sandoz AG Caspofungin formulations
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
JP5537425B2 (ja) 2007-06-26 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 凍結乾燥抗真菌組成物
US20100287884A1 (en) * 2007-10-25 2010-11-18 Sangita Seshadri Powder conditioning of unit dose drug packages
WO2009144739A1 (en) * 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
EP2504020A4 (en) 2009-11-23 2013-05-29 Eagle Pharmaceuticals Inc DAPTOMYCIN FORMULATIONS
TR201812823T4 (tr) 2009-11-23 2019-02-21 Cubist Pharmaceuticals Llc Lipopeptit bileşimleri ve ilgili yöntemler.
JP5902188B2 (ja) 2010-11-01 2016-04-13 メリンタ セラピューティクス，インコーポレイテッド 薬学的組成物
EP2655314B1 (en) 2010-12-23 2018-02-07 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof

Also Published As

Publication number Publication date
EP2504353B1 (en) 2018-07-11
SG10201407724YA (en) 2014-12-30
PE20151717A1 (es) 2015-11-19
FI2504353T4 (fi) 2023-11-30
BR112012012406B1 (pt) 2021-11-16
ECSP12011939A (es) 2012-07-31
JP2016147874A (ja) 2016-08-18
US9662397B2 (en) 2017-05-30
DK2504353T4 (da) 2023-11-20
EP3417849A1 (en) 2018-12-26
ES2686331T5 (es) 2024-03-27
CN108785654A (zh) 2018-11-13
ES2686331T3 (es) 2018-10-17
BR112012012406A2 (pt) 2019-12-03
EP2504353B2 (en) 2023-09-13
HRP20181380T4 (hr) 2023-11-10
JP6239167B2 (ja) 2017-11-29
CA2781666A1 (en) 2011-05-26
AU2010321531C1 (en) 2020-10-01
AU2010321531A2 (en) 2014-10-30
TR201812823T4 (tr) 2019-02-21
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
TW201703791A (zh) 2017-02-01
HUE039967T2 (hu) 2019-02-28
CN104056250A (zh) 2014-09-24
CA2781666C (en) 2017-02-21
HRP20181380T1 (hr) 2018-10-19
NZ600118A (en) 2014-08-29
US20140364380A1 (en) 2014-12-11
EP2504353A2 (en) 2012-10-03
CL2012001336A1 (es) 2012-10-05
AU2010321531B2 (en) 2016-11-03
RU2607526C2 (ru) 2017-01-10
DK2504353T3 (en) 2018-09-10
AR079127A1 (es) 2011-12-28
EP2504353A4 (en) 2014-04-02
JP2017075186A (ja) 2017-04-20
MX2012005993A (es) 2012-11-23
AR123846A2 (es) 2023-01-18
CN102712677B (zh) 2015-06-03
PL2504353T5 (pl) 2023-11-20
SI2504353T2 (sl) 2023-11-30
TWI548414B (zh) 2016-09-11
IL219891B (en) 2018-01-31
US9138456B2 (en) 2015-09-22
JP2013511557A (ja) 2013-04-04
US20120270772A1 (en) 2012-10-25
RS57566B1 (sr) 2018-10-31
PT2504353T (pt) 2018-10-18
WO2011063419A3 (en) 2011-10-13
RS57566B2 (sr) 2023-12-29
LT2504353T (lt) 2018-09-25
CO6541585A2 (es) 2012-10-16
PE20121517A1 (es) 2012-11-26
PL2504353T3 (pl) 2018-11-30
CN102712677A (zh) 2012-10-03
SI2504353T1 (sl) 2018-10-30
CY1120854T1 (el) 2019-12-11
JP6088681B2 (ja) 2017-03-01
US20160030577A1 (en) 2016-02-04
IL219891A0 (en) 2012-07-31
DOP2012000140A (es) 2012-10-30
JP6041673B2 (ja) 2016-12-14
RU2012126076A (ru) 2013-12-27
US8835382B2 (en) 2014-09-16
WO2011063419A2 (en) 2011-05-26
AU2010321531A1 (en) 2012-06-14
CR20120271A (es) 2012-08-01

Similar Documents

Publication Publication Date Title
CL2015002412A1 (es) Composición farmacéutica sólida de daptomicina; método de fabricación; y uso para tratar infecciones bacterianas (divisional de la sol. 1336-2012)
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
NZ612503A (en) Method for producing an aqueous stable chlorine dioxide solution
CO6382125A2 (es) Inhibidores de proteína quinasa
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2009005413A (es) Formas cristalinas del acido zoledronico.
RU2012155188A (ru) Композиции для ухода за полостью рта, устойчивые к микробному росту
MA34100B1 (fr) Compositions d'argile
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
EA201071167A1 (ru) Стабилизированные олеосомные композиции и способы их получения
TW200639159A (en) Treatment of pain
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
MX2012003615A (es) Composiciones de limpieza abrasivas, acidas, viscosas.
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
ATE420089T1 (de) Substituierte azachinazoline mit antiviraler wirkung
AR077915A1 (es) Forma cristalina de pemirolast
MY150201A (en) Cosmetic composition for external adminstration in spray form
NZ591529A (en) Chemical composition for skin care formulations
TW200833708A (en) Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
UA111145C2 (uk) Фармацевтична композиція